Company intelligence / Profile preview

Aluda Pharmaceuticals

Menlo Park, California, United Statesaludapharm.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Aluda’s lead candidate ALD-R491 targets vimentin to modulate immune responses and fibrosis. Preclinical data show significant efficacy in severe models of autoimmune and fibrotic diseases. The company is preparing for Phase I trials in sepsis with plans to expand into Crohn's disease with fibrotic strictures. Animal models demonstrate reversal of fibrosis and restoration of immune balance.[2][3][6][10]

Therapeutic areas: ImmunologyGastroenterologyPulmonologyInfectious Diseases
Modalities: Small molecules[3][6][7]
Industry: Biotech

Drug pipeline

4 assets

ALD-R5XX

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Academic collaborations with University of Oxford/Kennedy Institute of Rheumatology [2]Karolinska Institutet [2]

Beyond the preview

Go deeper on Aluda Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aluda Pharmaceuticals.

Explore the full profile